Diva Sansanwal

Diva Sansanwal

Auto-generated profile, based on publicly available information

Diva Sansanwal

Department of Pathology, Moores Cancer Center, Sanford Consortium for Regenerative Medicine at the University of California, San Diego, La Jolla, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Cancer Research Communications
Verified
Journal Article
Open access
CWChengsheng Wu
Chengsheng Wu
TSTami Von Schalscha
Tami Von Schalscha
DSDiva Sansanwal
Diva Sansanwal
CQChen Qian
Chen Qian
QJQinlin Jiang
Qinlin Jiang
DCDavid A. Cheresh
David A. Cheresh
Cancer-associated fibroblasts (CAF) generate an extracellular matrix (ECM) which provides a repository for factors that promote pancreatic cancer progression. In this study, we establish that CAF contribution to pancreatic tumor initiation, i.e., stemness, depends on fibronectin (FN) as a scaffold required for assembly of a collagen-containing fibrotic ECM with a critical dependence on the FN-binding integrins, α5β1 and αvβ3. CAF matrix assembly can be prevented by knockdown of FN, integrin α5, or integrin β3 or by a bispecific antibody with dual recognition of α5β1 and αvβ3 that can also destabilize a preexisting matrix. In mice, the ability of CAFs to produce a stiff collagenous matrix and accelerate tumor initiation can be blocked by knockdown of FN or FN-binding integrins or systemic treatment with the α5β1/αvβ3 bispecific antibody. Together, these results reveal that dual targeting of the FN-binding integrins, α5β1 and αvβ3, can block the ability of CAFs and their matrix to enhance pancreatic cancer stemness and progression. Significance: Simultaneous targeting of two integrins that function as receptors for FN, a protumor ECM protein, can prevent fibroblasts from supporting the malignant behavior of pancreatic cancer cells.

31 January 2025
Verified
Other
Open access
CWChengsheng Wu
Chengsheng Wu
TSTami Von Schalscha
Tami Von Schalscha
DSDiva Sansanwal
Diva Sansanwal
CQChen Qian
Chen Qian
QJQinlin Jiang
Qinlin Jiang
DCDavid A. Cheresh
David A. Cheresh
Validation of KP4-luc orthotopic pancreatic cancer model


31 January 2025
Verified
Other
Open access
CWChengsheng Wu
Chengsheng Wu
TSTami Von Schalscha
Tami Von Schalscha
DSDiva Sansanwal
Diva Sansanwal
CQChen Qian
Chen Qian
QJQinlin Jiang
Qinlin Jiang
DCDavid A. Cheresh
David A. Cheresh
FN-binding integrins mediate ECM production. Knockdown of FN or FN-binding integrins in CAFs prevents the formation of FN and COL fibers. CAF-1299 cells were treated with siRNA for a scramble control vs. FN, ITGA5, or ITGB3. After 72 hours, IF staining shows FN and COL content. The top set of images were not permeabilized. Images are representative of at least three independent experiments. Blots confirm knockdown. si-CTRL, CAFs with siRNA for a Universal Negative Control; si-FN, CAFs with siRNA-mediated knockdown of FN1; si-α5, CAFs with ITGA5 knockdown; si-β3, CAFs with ITGB3 knockdown.

31 January 2025
Verified
Other
Open access
CWChengsheng Wu
Chengsheng Wu
TSTami Von Schalscha
Tami Von Schalscha
DSDiva Sansanwal
Diva Sansanwal
CQChen Qian
Chen Qian
QJQinlin Jiang
Qinlin Jiang
DCDavid A. Cheresh
David A. Cheresh
BsAb improves the targeting of FN-binding integrins on CAFs. A, BsAb for dual recognition of αvβ3 and α5β1 heterodimers. Schematic depicts the design of a novel BsAb with monovalent recognition of two antigens, integrins αvβ3 and α5β1. The Fab domains for the BsAb are identical to the “control” bivalent (i.e., monospecific) mAb recognizing αvβ3 (derived from etaracizumab) and α5β1 (derived from volociximab). B, BsAb binding to cells compared with commercial and control antibodies. Flow cytometry plots show the binding of each antibody to CAF-1299 and CAF-1424. C, BsAb shows improved binding to CAFs compared with constituent mAbs. The graph shows median fluorescence intensity (MFI) for antibody binding to CAF-1299 and CAF-1424 cells. Bars and error bars represent SD from n = 3 independent experiments.

31 January 2025
Verified
Other
Open access
CWChengsheng Wu
Chengsheng Wu
TSTami Von Schalscha
Tami Von Schalscha
DSDiva Sansanwal
Diva Sansanwal
CQChen Qian
Chen Qian
QJQinlin Jiang
Qinlin Jiang
DCDavid A. Cheresh
David A. Cheresh
Effect of BsAb on primary fibroblasts isolated from patients with fibrotic disease